Teachers Advisors LLC raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 30.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 290,993 shares of the biotechnology company’s stock after buying an additional 68,207 shares during the period. Teachers Advisors LLC’s holdings in Sarepta Therapeutics were worth $8,613,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $645,000. Renaissance Technologies LLC purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $1,346,000. AQR Capital Management LLC increased its position in shares of Sarepta Therapeutics by 737.6% in the fourth quarter. AQR Capital Management LLC now owns 41,719 shares of the biotechnology company’s stock worth $1,144,000 after buying an additional 36,738 shares during the period. Norges Bank purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $11,181,000. Finally, Macquarie Group Ltd. purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $905,000. 73.09% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) opened at 40.58 on Friday. The company has a 50 day moving average of $35.31 and a 200-day moving average of $32.53. Sarepta Therapeutics, Inc. has a one year low of $22.61 and a one year high of $63.73. The firm’s market cap is $2.23 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. During the same period in the previous year, the business posted ($1.19) EPS. The firm’s quarterly revenue was up 350000.0% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics, Inc. will post ($1.17) earnings per share for the current year.
A number of brokerages have commented on SRPT. Piper Jaffray Companies set a $43.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 18th. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday. Vetr downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 target price on the stock. in a research note on Monday, May 15th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. Finally, BidaskClub downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Eight analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $61.28.
In other news, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total transaction of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sandesh Mahatme sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the sale, the chief financial officer now directly owns 41,736 shares of the company’s stock, valued at approximately $1,711,176. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 in the last three months. Corporate insiders own 9.60% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
